REGENXBIO Announces Participation in Key Investor Conferences

Upcoming Investor Conferences for REGENXBIO Inc.

REGENXBIO Inc. (Nasdaq: RGNX) has made an exciting announcement regarding its participation in several key upcoming investor conferences that hold significant value for stakeholders and potential investors alike. These conferences are great opportunities for REGENXBIO to showcase its innovative approach and advancements in gene therapy.

Wells Fargo Healthcare Conference

First on the agenda is the 2025 Wells Fargo Healthcare Conference, where REGENXBIO is set to engage in one-on-one investor meetings on an upcoming Thursday. This will allow direct interaction between the company and its investors, providing a platform for discussing the latest developments and potential future endeavors.

Morgan Stanley 23rd Annual Global Healthcare Conference

Following closely, REGENXBIO will take part in the renowned Morgan Stanley 23rd Annual Global Healthcare Conference. During this event, scheduled for a Monday, a special fireside chat is planned for 11:30 a.m. ET, where the company’s leaders will dive into discussions about their strategic goals and how REGENXBIO plans to advance its mission of improving lives through gene therapy.

Baird Global Healthcare Conference

Next, on the schedule is the Baird 2025 Global Healthcare Conference, unfolding with another engaging fireside chat. This session is set for a Tuesday morning at 8:30 a.m. ET. This conference serves as an additional avenue for REGENXBIO to connect with investors, shedding light on their ongoing projects and innovations.

H.C. Wainwright Annual Global Investment Conference

Moreover, REGENXBIO will also present at the H.C. Wainwright 27th Annual Global Investment Conference. This event is lined up for later in the same week, where another fireside chat will take place. This chat will focus on the company’s latest advancements in gene therapies and its expansive pipeline.

Access to Live Webcasts

For those interested in following along, REGENXBIO will be offering live webcasts of select fireside chats via its Investors section on the company’s website. Additionally, archived recordings will be available for a period of 30 days post-event, ensuring that stakeholders don’t miss out on any important information shared during these discussions.

About REGENXBIO Inc.

Founded in 2009, REGENXBIO has emerged as a leading biotechnology company dedicated to improving lives through the remarkable potential of gene therapy. The company is recognized for its pioneering efforts in the AAV (adeno-associated virus) gene therapy field, consistently working towards developing innovative solutions for rare diseases. REGENXBIO’s late-stage pipeline showcases treatments for various conditions, such as Duchenne muscular dystrophy and certain metabolic disorders, underscoring its commitment to transformative healthcare.

Contacts for Further Information

To learn more about REGENXBIO and its exciting advancements in gene therapy, interested parties can reach out to the corporate communications team. For investors looking for detailed insights, the investor relations department is available to provide additional information and answer any queries.

Frequently Asked Questions

1. When are the upcoming investor conferences for REGENXBIO?

REGENXBIO will participate in several conferences, starting with the Wells Fargo Healthcare Conference on September 4, followed by others through September 9.

2. How can I access the webcasts of the conferences?

Live webcasts of select fireside chats will be available on REGENXBIO’s website, with recordings accessible for approximately 30 days after the events.

3. What is the main focus of REGENXBIO?

The company focuses on improving lives through gene therapy, developing innovative treatments for rare and retinal diseases.

4. Who can I contact for more information?

For corporate communications, you can connect with the team at REGENXBIO, or reach out to the investor relations department for investment-related inquiries.

5. What types of therapies is REGENXBIO developing?

REGENXBIO is advancing a pipeline of one-time gene therapies targeting rare diseases, including treatments for Duchenne muscular dystrophy and metabolic disorders.

About The Author

Hello, I'm Thomas Cooper, a financial expert and writer passionate about helping people understand and navigate the financial world. Having a solid financial background and a lot of experience, my area of expertise is simplifying difficult financial ideas into useful, understandable guidance. My goal with my writings and blog entries is to provide you the information and resources you need to make wise financial choices.

I am thrilled to contribute my ideas and engage with a lively investor community at Investors Hangout, where I recently joined the team. My mission is to make finance interesting and approachable so you may take charge of your financial future. I appreciate you coming along on this path to success and financial knowledge.

Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.